| Literature DB >> 32315597 |
Stéphanie Herkenne1, Olivier Ek2, Margherita Zamberlan1, Anna Pellattiero1, Maya Chergova1, Iñigo Chivite3, Eliška Novotná1, Giovanni Rigoni2, Tiago Branco Fonseca1, Dijana Samardzic1, Andrielly Agnellini4, Camilla Bean1, Giulietta Di Benedetto5, Natascia Tiso2, Francesco Argenton2, Antonella Viola4, Maria Eugenia Soriano2, Marta Giacomello6, Elena Ziviani2, Gabriele Sales2, Marc Claret3, Mariona Graupera7, Luca Scorrano8.
Abstract
While endothelial cell (EC) function is influenced by mitochondrial metabolism, the role of mitochondrial dynamics in angiogenesis, the formation of new blood vessels from existing vasculature, is unknown. Here we show that the inner mitochondrial membrane mitochondrial fusion protein optic atrophy 1 (OPA1) is required for angiogenesis. In response to angiogenic stimuli, OPA1 levels rapidly increase to limit nuclear factor kappa-light-chain-enhancer of activated B cell (NFκB) signaling, ultimately allowing angiogenic genes expression and angiogenesis. Endothelial Opa1 is indeed required in an NFκB-dependent pathway essential for developmental and tumor angiogenesis, impacting tumor growth and metastatization. A first-in-class small molecule-specific OPA1 inhibitor confirms that EC Opa1 can be pharmacologically targeted to curtail tumor growth. Our data identify Opa1 as a crucial component of physiological and tumor angiogenesis.Entities:
Keywords: NFκB; Opa1; angiogenesis; cancer; fusion-fission; lymphangiogenesis; metastasis; mitochondria; mouse; tumor; zebrafish
Year: 2020 PMID: 32315597 DOI: 10.1016/j.cmet.2020.04.007
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287